Welcome to our dedicated page for Ekso Bionics Holdings news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings stock.
Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.
Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.
Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.
For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.
Ekso Bionics Holdings (Nasdaq: EKSO) has partnered with Performance Contracting, Inc. (PCI) to test its EVO™ exoskeleton vests in the construction sector. Over a year, PCI employees across six Bay Area counties will evaluate the technology to enhance product development. The EVO vest aims to reduce worker fatigue and injuries, boosting productivity. Michael Pratt of Ekso highlighted the importance of supporting their user base through flexible subscription offerings. PCI, emphasizing its commitment to employee well-being, plans to invest in innovative solutions to uphold its safety standards.
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology, announced that CFO Jack Glenn will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. An on-demand presentation will be available starting at 4:00 AM PT / 7:00 AM ET on March 9 and accessible throughout the conference via the company's website. Ekso Bionics specializes in innovative solutions that enhance strength, endurance, and mobility in both medical and industrial sectors, highlighting their commitment to advancing wearable robotics since 2005.
Ekso Bionics Holdings reported a Q4 2020 revenue of $2.3 million, down from $3.7 million in Q4 2019, with gross margins improving to approximately 60%. The company saw a net loss of $4 million ($0.48 per share) for the quarter, compared to $2.7 million in 2019. Full-year revenue was $8.9 million, a decrease from $13.9 million in 2019, largely attributed to COVID-19 impacts. Despite a 45% reduction in cash used for operations, the company raised $40 million from a public offering in February 2021 to bolster its growth strategy.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced financial results for Q4 and full year 2020 will be released on February 25, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results and recent business developments. Investors can participate by calling 877-407-3036 (domestic) or 201-378-4919 (international). A live webcast will be available in the "Investors" section of the company's website, with a replay accessible for two weeks afterward.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the completion of its public offering, closing 3,902,440 shares of common stock at $10.25 each. The offering generated approximately $40 million in gross proceeds, with a 30-day option for underwriters to purchase an additional 585,366 shares. The proceeds will be allocated towards working capital, debt repayment, acquisitions, and other corporate purposes. This offering was managed by H.C. Wainwright & Co. The shares were issued under a previously filed registration statement with the SEC.
Ekso Bionics has announced an increase in its public offering to 3,902,440 shares at $10.25 each, aiming to raise approximately $40 million before expenses. The offering, managed by H.C. Wainwright & Co., is set to close around February 11, 2021. Additionally, an option for the underwriter to purchase 585,366 more shares is included. The funds will be used for working capital, debt repayment, and other corporate purposes, indicating the company's intention for growth and strengthening its financial position.
Ekso Bionics has announced a firm commitment underwriting agreement with H.C. Wainwright & Co. to purchase 975,610 shares of common stock at $10.25 each, aiming to raise approximately $10 million. This offering is expected to close on February 11, 2021. Additionally, the underwriter has a 30-day option to buy another 146,341 shares. The proceeds will be used for working capital, debt repayment, and potential acquisitions. The offering is registered under Form S-3 with the SEC.
Ekso Bionics (Nasdaq: EKSO) announced preliminary financial results for Q4 and FY 2020, with Q4 revenue estimated at $2.3 million, down from $3.7 million in Q4 2019. Total revenue for FY 2020 is about $8.9 million, compared to $13.9 million in 2019. Cash reserves rose to $12.9 million from $10.9 million year-over-year. CEO Jack Peurach highlighted strong performance despite COVID-19 challenges and a new subscription model aimed to expand their market. The company plans to report complete results in late February 2021.
Ekso Bionics (Nasdaq: EKSO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. Jack Peurach, CEO, and Jack Glenn, CFO, will present at this event. An on-demand company presentation will be available starting January 11 at 6:00 AM ET on the company's website. Ekso Bionics specializes in exoskeleton technology aimed at enhancing strength and mobility for medical and industrial applications, furthering its mission to amplify human potential.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the election of Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors, effective December 29, 2020. Both directors bring extensive experience in business and healthcare. Cloyd has nearly 40 years of experience in public accounting and corporate governance, while Wallen has 25 years in life sciences and healthcare. Their insights are expected to enhance corporate strategy and value for stockholders as Ekso Bionics continues advancing its exoskeleton technology for medical and industrial applications.
FAQ
What is the current stock price of Ekso Bionics Holdings (EKSO)?
What is the market cap of Ekso Bionics Holdings (EKSO)?
What does Ekso Bionics Holdings, Inc. do?
Where is Ekso Bionics headquartered?
What are the main segments of Ekso Bionics?
What does the EksoHealth segment specialize in?
What does the EksoWorks segment focus on?
How has Ekso Bionics impacted people with paralysis?
In which regions does Ekso Bionics operate?
How can I get in touch with Ekso Bionics for investor relations?
What innovations has Ekso Bionics brought to the industrial market?
How does Ekso Bionics contribute to physical rehabilitation?
